Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

a and an established global regulatory and commercial

organization.

-- Sales of Aldurazyme(R) (laronidase) increased 38 percent to $37.0

million in the first quarter, compared with $26.8 million in the same

quarter a year ago. Genzyme now records sales of Aldurazyme on its top

line and makes tiered payments to BioMarin Pharmaceutical Inc. on

worldwide product sales under a restructured agreement between the

companies.

-- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent

in the first quarter to $33.8 million from $26.3 million, reflecting

ongoing improvement in thyroid cancer detection and well-established

treatment guidelines. The use of Thyrogen in ablation procedures is

also contributing to the product's growth, following the December 2007

U.S. approval for this indication.

-- Within the Renal business, sales of sevelamer therapies Renagel(R)

(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million

from $137.4 million in the first quarter last year. In March, Genzyme

launched Renvela in the United States, where the company is engaged in

active discussions with the FDA to expand the product's labeling to

include chronic kidney disease patients with hyperphosphatemia who are

not on dialysis. The three companies that currently market phosphate

binders are working collaboratively to provide the FDA with information

that will help the agency determine the appropriate treatment paradigm

for these patients. Genzyme anticipates that the Renvela label

expansion will take place at the latest by the middle of 2009. Genzyme

has also filed for European approval for Renvela in both the dialysis

and chronic kidney disease indications.

-- Within the Transplant business, first-quarter sales of Thymoglobulin(R)
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... LOS ANGELES , July 23, 2014 /PRNewswire-iReach/ -- ... enhance cognitive performance for the long term. They are ... competitive edge of sustained energy as an alternative to ... launch Think Drinks on Indiegogo on July 29, 2014, ... the 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... DENVER , July 23, 2014  Having the ... making is vital to accelerating business growth and achieving ... American Hospital Association (AHA) Leadership Summit, July 20-22, 2014, ... prestigious panel of hospital executives and healthcare experts discussing ... Joanne Carrocino , President & Chief Executive Officer ...
(Date:7/23/2014)... 23, 2014 DuPont Pioneer announced today ... vice president of Agricultural Biotechnology (ABT), effective July 21, ... served most recently as president, chief executive officer and ... leadership in the seed and crop protection industry to ... E. Schickler , president of DuPont Pioneer. “I am ...
(Date:7/23/2014)... July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a ... is filing for two medical marijuana dispensary locations in ... addition to the Clark County, Nevada ... permit, as previously announced.  GrowBLOX Sciences, CEO ... two new applications for dispensaries in the City ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, ... "Company"),one of the leading plasma-based pharmaceutical companies in the ... hosted a forum of,industry experts on July 10 - ... discuss future development strategies for the Company. , ...
... , , , ... announced today that it had closed its series A financing round. The infusion ... of technology that converts a wide variety of cellulosic materials (such as algae, ... , As part of the agreement, the lead investor ...
... , HALIFAX, July 15 /PRNewswire/ - Scientists in Atlantic Canada ... skin aging. Researchers were investigating the genetic cause of a ... causes skin on the hands, feet and face to be ... delays including effects on the brain. In the process, researchers ...
Cached Biology Technology:China Biologic Products Hosts its First Forum for Strategy and Development 2China Biologic Products Hosts its First Forum for Strategy and Development 3Canadian researchers discover gene related to the appearance of aging 2
(Date:7/23/2014)... by satellite over a 15-year period off the U.S. ... feed in specific locations each year, according to a ... PLOS ONE by Ladd Irvine from Oregon ... to mitigate human threats to the whale population. , ... recover since the establishment of protections in the mid-1960s. ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
(Date:7/23/2014)... , , , , , , , , ... , , , , , ... researchers are proposing that changing how medical care is delivered could help prevent multiple chronic diseases and extend healthy lifespan. The idea, they argue, would be ... , , , , , ... , , , , , ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... gets his new laser laboratory operational later this year, ... to pluck molecular bonds like a stringed musical instrument. ... of Chemistry, arrived at the University of Chicago in ... aid of ultrafast vibrational spectroscopy methods that he has ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
... March 12, 2013  Spiral Genetics, a cloud-based big data ... A financing, led by venture capital firm DFJ.  The ... create revolutionary tools that empower the bioinformatics community to ... company intends to use the funds to expand its ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 2Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: